CL2012000391A1 - Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina. - Google Patents

Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.

Info

Publication number
CL2012000391A1
CL2012000391A1 CL2012000391A CL2012000391A CL2012000391A1 CL 2012000391 A1 CL2012000391 A1 CL 2012000391A1 CL 2012000391 A CL2012000391 A CL 2012000391A CL 2012000391 A CL2012000391 A CL 2012000391A CL 2012000391 A1 CL2012000391 A1 CL 2012000391A1
Authority
CL
Chile
Prior art keywords
amount
asn297
bendamustine
oligosaccharides
antibody
Prior art date
Application number
CL2012000391A
Other languages
English (en)
Spanish (es)
Inventor
Frank Herting
Christian Klein
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2012000391A1 publication Critical patent/CL2012000391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012000391A 2009-08-14 2012-02-14 Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina. CL2012000391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14

Publications (1)

Publication Number Publication Date
CL2012000391A1 true CL2012000391A1 (es) 2012-08-24

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000391A CL2012000391A1 (es) 2009-08-14 2012-02-14 Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.

Country Status (34)

Country Link
US (4) US20110165151A1 (pl)
EP (1) EP2464382B1 (pl)
JP (3) JP5646626B2 (pl)
KR (1) KR101425736B1 (pl)
CN (2) CN102596245A (pl)
AR (1) AR077866A1 (pl)
AU (1) AU2010281866B2 (pl)
CA (1) CA2769674C (pl)
CL (1) CL2012000391A1 (pl)
CR (1) CR20120036A (pl)
CY (2) CY1119251T1 (pl)
DK (1) DK2464382T3 (pl)
ES (1) ES2630158T3 (pl)
HK (1) HK1245145A1 (pl)
HR (1) HRP20170972T1 (pl)
HU (2) HUE033531T2 (pl)
IL (1) IL217753A (pl)
LT (2) LT2464382T (pl)
LU (1) LUC00045I2 (pl)
MA (1) MA33469B1 (pl)
MX (2) MX355849B (pl)
MY (1) MY163003A (pl)
NO (1) NO2017054I1 (pl)
NZ (1) NZ597666A (pl)
PL (1) PL2464382T3 (pl)
PT (1) PT2464382T (pl)
RS (1) RS56146B1 (pl)
SG (1) SG178324A1 (pl)
SI (1) SI2464382T1 (pl)
SM (1) SMT201700329T1 (pl)
TW (1) TWI409079B (pl)
UA (1) UA110096C2 (pl)
WO (1) WO2011018224A1 (pl)
ZA (1) ZA201200830B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HRP20220224T1 (hr) * 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
CA2911962A1 (en) * 2013-06-07 2014-12-11 Roy H. Larsen Method for upregulating antigen expression
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
MXPA05012421A (es) * 2003-05-16 2006-02-22 Hybridon Inc Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2006114700A2 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
KR20140133958A (ko) * 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CN102395619B (zh) * 2009-04-15 2013-06-12 因温斯特技术公司 改进否则不溶混的化合物的溶混性

Also Published As

Publication number Publication date
MA33469B1 (fr) 2012-07-03
JP2013501740A (ja) 2013-01-17
CN102596245A (zh) 2012-07-18
JP2015071611A (ja) 2015-04-16
IL217753A0 (en) 2012-03-29
MX355849B (es) 2018-05-02
PL2464382T3 (pl) 2017-09-29
US20160166688A9 (en) 2016-06-16
CY2017034I1 (el) 2018-02-14
ES2630158T3 (es) 2017-08-18
CY2017034I2 (el) 2018-02-14
DK2464382T3 (en) 2017-07-17
NZ597666A (en) 2013-10-25
CR20120036A (es) 2012-04-18
US20140044705A1 (en) 2014-02-13
NO2017054I1 (no) 2017-10-26
KR20120054068A (ko) 2012-05-29
AU2010281866A1 (en) 2012-02-02
CY1119251T1 (el) 2018-02-14
CA2769674A1 (en) 2011-02-17
LUC00045I1 (pl) 2017-11-03
SMT201700329T1 (it) 2017-09-07
US20120315268A1 (en) 2012-12-13
MY163003A (en) 2017-07-31
AU2010281866B2 (en) 2016-05-12
EP2464382B1 (en) 2017-05-03
AR077866A1 (es) 2011-09-28
LUC00045I2 (pl) 2018-02-26
WO2011018224A1 (en) 2011-02-17
JP5646626B2 (ja) 2014-12-24
PT2464382T (pt) 2017-06-30
LT2464382T (lt) 2017-07-25
JP5963013B2 (ja) 2016-08-03
UA110096C2 (uk) 2015-11-25
HRP20170972T1 (hr) 2017-09-22
MX2012001782A (es) 2012-04-19
HUS1700041I1 (hu) 2017-11-28
JP2016222673A (ja) 2016-12-28
KR101425736B1 (ko) 2014-08-01
BR112012002855A2 (pt) 2016-11-01
LTPA2017035I1 (lt) 2017-11-27
CN107261138A (zh) 2017-10-20
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
RU2012109445A (ru) 2013-09-27
ZA201200830B (en) 2012-10-31
TW201110980A (en) 2011-04-01
EP2464382A1 (en) 2012-06-20
HK1245145A1 (zh) 2018-08-24
HUS000498I2 (hu) 2021-03-29
HUE033531T2 (hu) 2021-12-28
US20150093376A1 (en) 2015-04-02
CA2769674C (en) 2018-01-23
RS56146B1 (sr) 2017-11-30
TWI409079B (zh) 2013-09-21
SG178324A1 (en) 2012-03-29
IL217753A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
CL2012000391A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
SG10201610247QA (en) Antibody variants having modifications in the constant region
BRPI1009824A2 (pt) dispersão sólida e forma farmacêutica sólida.
EP2538976B8 (en) Immunoconjugates against folate receptor 1 and uses thereof
BRPI0920216A2 (pt) forma de dosagem intraoral em múltiplas porções e uso das mesmas
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
ZA201001442B (en) Combination therapy with type i and type ii anti-cd20 antibodies
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
BR112012005208A2 (pt) antiocorpos contra o receptor de glucagon e seu uso
CA122665S (en) Trigger latch
EP2351526A4 (en) RADIATION IMAGING
IL205713A0 (en) Afucosylated antibodies against ccr5 and their use
SI2303930T1 (sl) Sulfatirana polisaharidna spojina in priprava ter uporaba le-te
AR082693A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
SI2266619T1 (sl) Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
BRPI0823334A2 (pt) Conexoes rosqueadas no campo petrolifero
GB0813973D0 (en) Saftey lighting
GB0707514D0 (en) Saftey line
ZA201005875B (en) Use of interleukin-1 conjugates in the treatment of diabetes